
Quarterly report 2025-Q3
added 11-06-2025
NeuroBo Pharmaceuticals Market Cap 2011-2026 | NRBO
As of February 25, 2026 NeuroBo Pharmaceuticals has a market cap of $ 12 M
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap NeuroBo Pharmaceuticals
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 20.7 M | 212 K | 802 K | 84.1 M | 44.5 M | 13.7 M | 106 M | 60.2 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 106 M | 212 K | 41.3 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Biotechnology industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
315 M | - | 2.43 % | $ 254 M | ||
|
ARCA biopharma
ABIO
|
484 M | - | 1052.0 % | $ 415 M | ||
|
Acasti Pharma
ACST
|
40.7 M | - | 4.01 % | $ 150 M | ||
|
AC Immune SA
ACIU
|
305 M | $ 2.72 | 7.51 % | $ 229 M | ||
|
Adverum Biotechnologies
ADVM
|
76.4 M | - | - | $ 86.2 M | ||
|
AgeX Therapeutics
AGE
|
14.1 K | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
724 M | - | - | $ 1.01 B | ||
|
AIkido Pharma
AIKI
|
19.6 M | - | 1.93 % | $ 17.4 M | ||
|
Aptorum Group Limited
APM
|
4.09 M | $ 0.81 | 1.28 % | $ 4.42 M | ||
|
I-Mab
IMAB
|
127 M | - | - | $ 866 M | ||
|
argenx SE
ARGX
|
13.8 B | $ 840.28 | 1.7 % | $ 25 B | ||
|
Ascendis Pharma A/S
ASND
|
7.37 B | $ 234.99 | 0.02 % | $ 5 B | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
33.6 B | - | - | $ 40.3 B | ||
|
Akero Therapeutics
AKRO
|
3.25 B | - | - | $ 3.67 B | ||
|
Biophytis SA
BPTS
|
549 M | - | -13.47 % | $ 169 M | ||
|
Albireo Pharma
ALBO
|
538 M | - | -0.23 % | $ 916 M | ||
|
Alterity Therapeutics Limited
ATHE
|
895 M | $ 3.33 | 0.79 % | $ 8.01 B | ||
|
Atea Pharmaceuticals
AVIR
|
254 M | $ 4.65 | 1.31 % | $ 392 M | ||
|
Allena Pharmaceuticals
ALNA
|
71.4 M | - | 3.16 % | $ 1.9 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
28.9 M | - | -1.52 % | $ 24.7 M | ||
|
AlloVir
ALVR
|
49 M | - | 4.14 % | $ 49.1 M | ||
|
Midatech Pharma plc
MTP
|
79 M | - | -18.52 % | $ 27.3 M | ||
|
Akouos
AKUS
|
172 M | - | 0.23 % | $ 488 M | ||
|
BioVie
BIVI
|
2.44 M | $ 1.25 | - | $ 1.85 M | ||
|
Ampio Pharmaceuticals
AMPE
|
664 K | - | -11.43 % | $ 502 K | ||
|
Applied Molecular Transport
AMTI
|
22.1 M | - | - | $ 10.1 M | ||
|
BioMarin Pharmaceutical
BMRN
|
13.1 B | $ 62.62 | -0.48 % | $ 11.9 B | ||
|
Acorda Therapeutics
ACOR
|
16.7 M | - | -24.86 % | $ 820 K | ||
|
Acer Therapeutics
ACER
|
12.1 M | - | 2.71 % | $ 14 M | ||
|
Aravive
ARAV
|
60.4 M | - | -13.39 % | $ 1.45 M | ||
|
Capricor Therapeutics
CAPR
|
155 M | $ 27.91 | 0.14 % | $ 747 M | ||
|
Институт стволовых клеток человека
ISKJ
|
2.83 B | - | - | - | ||
|
CASI Pharmaceuticals
CASI
|
1.09 B | $ 0.8 | 5.68 % | $ 109 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
32.8 M | - | - | $ 26.5 M | ||
|
Avenue Therapeutics
ATXI
|
544 K | - | -52.27 % | $ 4.45 M | ||
|
Catalyst Biosciences
CBIO
|
33.6 M | $ 12.65 | 10.29 % | $ 833 M | ||
|
Axsome Therapeutics
AXSM
|
8.67 B | $ 169.95 | -2.75 % | $ 8.45 B | ||
|
Ayala Pharmaceuticals
AYLA
|
7.72 M | - | - | $ 7.46 M | ||
|
Atreca
BCEL
|
49 M | - | -11.76 % | $ 5.79 M | ||
|
Alpine Immune Sciences
ALPN
|
269 M | - | - | $ 2.17 B | ||
|
BioDelivery Sciences International
BDSI
|
308 M | - | -4.8 % | $ 255 M | ||
|
Aeterna Zentaris
AEZS
|
41.4 M | - | 5.93 % | $ 314 M | ||
|
BeiGene, Ltd.
BGNE
|
253 B | - | 0.49 % | $ 251 B | ||
|
Biogen
BIIB
|
29.4 B | $ 195.13 | -0.62 % | $ 28.6 B | ||
|
Cellectis S.A.
CLLS
|
203 M | $ 3.98 | 0.51 % | $ 116 M | ||
|
Bellicum Pharmaceuticals
BLCM
|
8.32 M | - | -9.72 % | $ 5.89 M | ||
|
Baudax Bio
BXRX
|
779 K | - | 0.59 % | $ 63 K | ||
|
Aptose Biosciences
APTO
|
2.32 M | - | -45.71 % | $ 1.2 M | ||
|
Aptinyx
APTX
|
9.48 M | - | -39.0 % | $ 4.57 M | ||
|
Cellectar Biosciences
CLRB
|
44.5 M | $ 3.36 | 3.07 % | $ 41.1 M |